1
|
Non-small Cell Lung Cancer Collaborative
Group. Chemotherapy in non-small cell lung cancer: a meta-analysis
using updated data on individual patients from 52 randomised
clinical trials. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
|
2
|
Shepherd FA, Dancey J, Ramlau R, et al:
Prospective randomized trial of docetaxel versus best supportive
care in patients with non-small-cell lung cancer previously treated
with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103.
2000.
|
3
|
Cappuzzo F, Gregorc V, Rossi E, et al:
Gefitinib in pretreated non-small cell lung cancer (NSCLC):
analysis of efficacy and correlation with HER2 and epidermal growth
factor receptor expression in locally advanced or metastatic NSCLC.
J Clin Oncol. 21:2658–2663. 2003. View Article : Google Scholar : PubMed/NCBI
|
4
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bunn PA Jr and Kelly K: New
chemotherapeutic agents prolong survival and improve quality of
life in non-small cell lung cancer: a review of the literature and
future directions. Clin Cancer Res. 4:1087–1100. 1998.PubMed/NCBI
|
6
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
8
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
9
|
Murillo JR Jr and Koeller J: Chemotherapy
given near the end of life by community oncologists for advanced
non-small cell lung cancer. Oncologist. 11:1095–1099. 2006.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Belani CP, Barstis J, La Rocca RV, et al:
Meta-analysis of weekly paclitaxel as maintenance therapy for
advanced non-small cell lung cancer patients following initial
chemotherapy. Lung Cancer. 49:332005. View Article : Google Scholar
|
11
|
Belani CP, Barstis J, Perry MC, et al:
Multicenter, randomized trial for stage IIIB or IV non-small cell
lung cancer using weekly paclitaxel and carboplatin followed by
maintenance weekly paclitaxel or observation. J Clin Oncol.
21:2933–2939. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: recent
advances and future directions. Oncologist. 13:5–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Brodowicz T, Krzakowski M, Zwitter M, et
al: Cisplatin and gemcitabine first-line chemotherapy followed by
maintenance gemcitabine or best supportive care in advanced
non-small cell lung cancer: a phase III trial. Lung Cancer.
52:155–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Fidias P, Dahkil SR, Lyss AP, et al:
Updated report of a phase III study of induction therapy with
gemcitabine + carboplatin (GC) followed by either delayed vs.
immediate second-line therapy with docetaxel (D) in advanced
non-small cell lung cancer. J Clin Oncol. 24:70322006.
|
15
|
Grossi F, Aita M, Follador A, et al:
Sequential, alternating and maintenance/consolidation chemotherapy
in advanced non-small cell lung cancer: a review of the literature.
Oncologist. 12:451–464. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Paesmans M, Sculier JP, Libert P, et al:
Response to chemotherapy has predictive value for further survival
of patients with advanced non-small cell lung cancer: 10 years
experience of the European Lung Cancer Working Party. Eur J Cancer.
33:2326–2332. 1997.PubMed/NCBI
|
17
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan and oxaliplatin combinations in patients with previously
untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30.
2004. View Article : Google Scholar
|
18
|
Grothey A and Sargent D: Overall survival
of patients with advanced colorectal cancer correlates with
availability of fluorouracil, irinotecan and oxaliplatin regardless
of whether doublet or single-agent therapy is used first line. J
Clin Oncol. 23:9441–9442. 2005. View Article : Google Scholar
|
19
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tournigand C, Andre T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Scagliotti GV, Parikh P, Von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Einhorn LH: First-line chemotherapy for
non-small cell lung cancer: is there a superior regimen based on
histology? J Clin Oncol. 26:3485–3486. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Yano T, Miura N, Takenaka T, et al:
Never-smoking non-small cell lung cancer as a separate entity:
clinicopathologic features and survival. Cancer. 113:1012–1018.
2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhou W, Heist RS, Liu G, et al: Smoking
cessation before diagnosis and survival in early stage non-small
cell lung cancer patients. Lung Cancer. 53:375–380. 2006.
View Article : Google Scholar : PubMed/NCBI
|